Historically, Acute promyelocytic leukemia (APL or AML-M3) is one of the most lethal forms of acute myeloid leukemia with distinct clinical and histopathologic features.
Acute promyelocytic leukemia is characterized by a unique chromosomal translocation involving the retinoic acid receptor-alpha gene on chromosome 17 (RARA). In greater than 99% of cases of APL, retinoic acid receptor-alpha (RARA) gene on chromosome 17 is involved in a reciprocal translocation with the promyelocytic leukemia gene (PML) on chromosome 15, a translocation denoted as t(15;17)(q22;q12)
Depending on the location of breakpoints within the PML site, intron 6, exon 6 and intron 3, the respective PML-RARa transcript subtypes referred to as long (L or bcr1), variant (V or bcr2) and short (S or bcr3), may be formed representing 55%, 5% and 40% of the cases respectively. The presence of PML/RARA t(15;17) translocation is necessary for response to all-trans-retinoic acid and arsenic trioxide. Thus, the PML/RARA t(15;17) assay is useful for diagnosis and predicting treatment response. It is also helpful for monitoring therapeutic response and MRD and for detecting early relapse.
|#||Product||Cat. No.||Reaction size/kit|
|1||Oncoscreen PML RARA bcr1 Quantitative PCR kit||OPLQ25||25|
|2||Oncoscreen PML RARA bcr1 Quantitative PCR kit||OPLQ50||50|
|3||Oncoscreen PML RARA bcr1 and bcr3 Quantitative PCR kit||OPLSQ25||25|
|4||Oncoscreen PML RARA bcr1 and bcr3 Quantitative PCR kit||OPLSQ50||50|
|5||Oncoscreen PML RARA bcr1 and bcr3 Quantitative PCR kit||OPLSQ100||100|